Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
Clinical trial NCT03447678 · UNKNOWN
Trial details
- NCT number
- NCT03447678
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-23
- Primary completion
- 2022-05-31
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.